Pyxis Oncology develops experimental cancer drugs, led by an antibody drug conjugate for head and neck squamous cell carcinoma. PYXS reports earnings on Mon, Nov 2, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for PYXS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in PYXS in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYXS is in one of them and how their past PYXS trades turned out.
Pyxis Oncology is a cancer drug developer based in Boston, Massachusetts. Its lead product candidate, micvotabart pelidotin, is an experimental antibody drug conjugate that targets a protein found in the tissue surrounding tumors rather than on cancer cells themselves. The company is focused on head and neck squamous cell carcinoma and is testing the drug alone and together with Keytruda, an immunotherapy made by Merck. The drug is still in clinical testing and is not approved for sale, and it is aimed at patients with solid tumors.
